Get started
Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

ALNY chart


Full chart

ALNY upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪30.69 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.62 USD
Net income (FY)
‪−440.24 M‬ USD
Revenue (FY)
‪1.83 B‬ USD
Shares float
‪127.94 M‬
Beta (1Y)
0.85

Employees


Employees (FY)
‪2.1 K‬
Change (1Y)
+98 +4.90%
Revenue / Employee (1Y)
‪870.62 K‬ USD
Net income / Employee (1Y)
‪−209.64 K‬ USD

About Alnylam Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Yvonne L. Greenstreet
Headquarters
Cambridge
Website
alnylam.com
Founded
2002
FIGI
BBG000BFGNJ5
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ALNY news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ALNY highest yielding bonds


ALNY5653584
Alnylam Pharmaceuticals, Inc. 1.0% 15-SEP-2027
Yield to maturity
−1.53%
Maturity date
Sep 15, 2027

Explore more bonds 

Sparks


Curated watchlists where ALNY is featured.

See all sparks 

Frequently Asked Questions


The current price of ALNY is 234.51 USD — it has decreased by −1.72% in the past 24 hours. Watch Alnylam Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Alnylam Pharmaceuticals, Inc. stocks are traded under the ticker ALNY.
ALNY stock has fallen by −4.40% compared to the previous week, the month change is a −6.67% fall, over the last year Alnylam Pharmaceuticals, Inc. has showed a 20.00% increase.
We've gathered analysts' opinions on Alnylam Pharmaceuticals, Inc. future price: according to them, ALNY price has a max estimate of 400.00 USD and a min estimate of 178.00 USD. Watch ALNY chart and read a more detailed Alnylam Pharmaceuticals, Inc. stock forecast: see what analysts think of Alnylam Pharmaceuticals, Inc. and suggest that you do with its stocks.
ALNY reached its all-time high on Oct 17, 2024 with the price of 304.39 USD, and its all-time low was 3.65 USD and was reached on Aug 18, 2004. View more price dynamics on ALNY chart.
See other stocks reaching their highest and lowest prices.
ALNY stock is 2.13% volatile and has beta coefficient of 0.85. Track Alnylam Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Alnylam Pharmaceuticals, Inc. there?
Today Alnylam Pharmaceuticals, Inc. has the market capitalization of ‪30.69 B‬, it has increased by 2.24% over the last week.
Yes, you can track Alnylam Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Alnylam Pharmaceuticals, Inc. is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
ALNY earnings for the last quarter are −0.87 USD per share, whereas the estimation was −0.92 USD resulting in a 5.09% surprise. The estimated earnings for the next quarter are −0.56 USD per share. See more details about Alnylam Pharmaceuticals, Inc. earnings.
Alnylam Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪500.92 M‬ USD, despite the estimated figure of ‪532.91 M‬ USD. In the next quarter, revenue is expected to reach ‪580.61 M‬ USD.
ALNY net income for the last quarter is ‪−111.57 M‬ USD, while the quarter before that showed ‪−16.89 M‬ USD of net income which accounts for −560.61% change. Track more Alnylam Pharmaceuticals, Inc. financial stats to get the full picture.
No, ALNY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has ‪2.10 K‬ employees. See our rating of the largest employees — is Alnylam Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Alnylam Pharmaceuticals, Inc. EBITDA is ‪−132.15 M‬ USD, and current EBITDA margin is −12.48%. See more stats in Alnylam Pharmaceuticals, Inc. financial statements.
Like other stocks, ALNY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Alnylam Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Alnylam Pharmaceuticals, Inc. technincal analysis shows the strong sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Alnylam Pharmaceuticals, Inc. stock shows the strong buy signal. See more of Alnylam Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.